Progen Co., Ltd.

Equities

A296160

KR7296160005

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 03/07/2024 BST			5-day change	1st Jan Change
6,170 ^KRW	+2.83%		+4.05%	-13.71%

06-24	Rani Therapeutics Holdings, Inc. Announces Partnership with ProGen Co., Ltd. on Development of Oral Obesity Treatment	CI
01-31	Progen Co., Ltd. announced that it expects to receive KRW 9.71405799 billion in funding from Yuhan Corporation	CI

Progen Co., Ltd. announced that it expects to receive KRW 9.71405799 billion in funding from Yuhan Corporation

January 30, 2024

Progen Co., Ltd. announced a private placement of 1,310,939 registered convertible preferred stock at the price of KRW 7,410 per share for gross proceeds of KRW 9,714,057,990 on January 31, 2024. The transaction has been approved by board of directors of the company.

Latest news about Progen Co., Ltd.

Rani Therapeutics Holdings, Inc. Announces Partnership with ProGen Co., Ltd. on Development of Oral Obesity Treatment	06-24	CI
Progen Co., Ltd. announced that it expects to receive KRW 9.71405799 billion in funding from Yuhan Corporation	01-30	CI

Chart Progen Co., Ltd.

Duration

Period

More charts

Company Profile

Progen Co Ltd is a Korea-based company principally engaged in the researching and developing new drugs. The Company produces metabolic disease treatment drugs, immune disease treatment drugs, immune anticancer drugs, and others. The Company was established in 1998.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROGEN CO., LTD.	-13.71%	50.07M
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+41.02%	39.84B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.02B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research